# Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

> **NCT01469832** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Institute for Regenerative Medicine** · enrollment: 12 (actual)

## Conditions studied

- Stargardt's Macular Dystrophy

## Interventions

- **BIOLOGICAL:** MA09-hRPE

## Key facts

- **NCT ID:** NCT01469832
- **Lead sponsor:** Astellas Institute for Regenerative Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-13
- **Primary completion:** 2015-09-30
- **Final completion:** 2015-09-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469832, "Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01469832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*